Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness

Core Insights - Fractyl Health, Inc. has appointed Lara Smith Weber as Chief Financial Officer, effective January 12, 2026, to oversee finance, accounting, and investor relations, and to support the executive leadership team and Board of Directors [1][3] Company Overview - Fractyl Health is a metabolic therapeutics company focused on innovative treatments for obesity and type 2 diabetes (T2D), aiming to shift from chronic management to durable disease-modifying therapies [5] - The company has a strong intellectual property portfolio, with 35 granted U.S. patents and approximately 45 pending U.S. applications, alongside numerous foreign patents [5] Leadership Transition - Lara Smith Weber brings over 20 years of financial leadership experience in medtech and biotech, with a proven track record in building financial organizations and guiding companies through operational scaling [2][3] - Ms. Smith Weber's previous roles include CFO at Inari and ONWARD Medical, where she strengthened capital structures and financial systems [3] - Lisa Davidson, the former CFO, resigned effective December 31, 2025, after ten years with the company, during which she played a key role in its growth and IPO [4][5]